Expired Study
This study is not currently recruiting Study Participants on ClinicalConnection.com. If you would like to find active studies please search for clinical trials.

Salt Lake City, Utah


Purpose:

This study will evaluate the pharmacokinetics of brimonidine following a single intravitreal administration of the 200 ug or 400 ug Brimonidine Tartrate Posterior Segment Drug Delivery System in patients 2, 4 or 8 weeks prior to undergoing a pars plana vitrectomy.


Criteria:

Inclusion Criteria: - Plan on having a pars plana vitrectomy for repair of a posterior segment condition (eg, epiretinal membrane, macular hole, vitreomacular traction) - Visual acuity in the non-study eye better than 20/200 Exclusion Criteria: - History of pars plana vitrectomy or retinal detachment surgery in the study eye - Surgery or laser treatment in the study eye within 3 months - Use of brimonidine, apraclonidine or other topical alpha-2-agonist in either eye within 2 weeks - Intraocular infection or inflammation


NCT ID:

NCT01229410


Primary Contact:

Study Director
Medical Director
Allergan


Backup Contact:

N/A


Location Contact:

Salt Lake City, Utah
United States



There is no listed contact information for this specific location.

Site Status: N/A


Data Source: ClinicalTrials.gov

Date Processed: August 31, 2019

Modifications to this listing: Only selected fields are shown, please use the link below to view all information about this clinical trial.


Click to view Full Listing

This study is not currently recruiting Study Participants on ClinicalConnection.com. The form below is not enabled.